Commentary · 28 Mar 2023
ArticlePublished 30 Mar 2023
Stem cell bioprocessing
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
In order to advance the goal of employing stem cells for cell treatment, the Stem Cell Bioprocessing Group is concentrated on creating scalable cell growth technologies using a micro-carrier platform. Commercial cell production cannot be scaled up using conventional techniques for flask- and tray-based generation of anchorage-dependent stem cells. The potential of stem cell research for tissue engineering-based therapeutics and clinical applications in regenerative medicine has been thoroughly recognised in recent years. Chung developed the first complete organ transplant in 2006 utilising adult stem cells and a clinical evaluation scaffold. Seven patients with myelomeningocele who received bladder transplants made possible by stem cell therapy saw significant improvements in their quality of life, marking a new milestone. Although the bladder is a fairly straightforward organ, the discovery shows the amazing advantages of the multidisciplinary approach of tissue engineering and regenerative medicine (TERM), which includes stem cell study and stem cell bioprocessing. Undoubtedly, the application of engineering principles and practises is required in the development of bioprocess technologies for the transfer of the current laboratory-based practise of stem cell tissue culture to the clinic as therapeutics in order to achieve control, reproducibility, automation, validation, and safety of the process and the product. Fundamental research (from embryonic biology to the ‘omics’ technologies and developments in immunology) and current industry experience (biologics), particularly on automation, quality assurance, and regulation, will need to contribute to the effective translation. It will be crucial to design, integrate, and implement various components on time; mistakes made in the past with regard to marketing, pricing, production, and advertising (such as when skin analogues were commercialised) shouldn’t be repeated.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Review article · 15 Jul 2016
Bioprocess engineering: micromanaging Chinese hamster ovary cell phenotypes
Short communication · 27 May 2023
Tools for the Enlargement of Stem Cell Therapy Products: Bioprocess Economic Forming
Review article · 20 May 2016
Stem cell biology, bioprocessing and therapeutic applications in various human and animal diseases
Conference abstract · 3 Sep 2018
Bioprocess Development for High-Density Culture of Human Induced Pluripotent Stem Cells in Bioreactor
More from this journal
The newest in Pharmaceutical Bioprocessing.
Article · 26 Feb 2026
Evolution and Production of a Clinical-Grade Adenovirus Expressing the Transgene Tissue Inhibitor of Metalloproteinase-3 (TIMP-3) Through Genome Engineering
Article · 29 Nov 2025
Adaptive Bioprocess Control: Enabling Intelligent and Robust Biomanufacturing
Article · 29 Nov 2025
Advanced Foam Control Strategies in Bioprocessing
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Bioprocessing
- SubjectPharmaceutical Sciences
- SubjectBiochemistry & Biotechnology
- BylineArticles whose byline prints “Erik Klaus”
